GSK gepotidacin edges closer to landmark approval for gonorrhoea.
Drugmaker GSK moved closer to expanding its antibiotic portfolio on Monday, after US regulators accepted its application to review gepotidacin as a potential oral treatment for gonorrhoea.
GSK
11 August 2025 07:37:05
Source: Sharecast
The FDA's priority review follows positive phase III data from the EAGLE-1 trial, which showed gepotidacin delivered a 92.6% success rate at the urogenital site, compared to 91.2% for the standard combination of intramuscular ceftriaxone and oral azithromycin.
If approved, GSK's gepotidacin would be the first oral option for treating uncomplicated urogenital gonorrhoea in patients aged 12 and over, offer a new option to US patients currently relying on injectable treatments. The FDA has set a decision date of 11 December under the Prescription Drug User Fee Act.
Review of regulatory submissions for the uncomplicated urinary tract infection indication was also ongoing in both the UK and Australia.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
